Law Offices of Howard G. Smith announces an investigation on behalf of Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ: ERAS) investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ERASCA, INC. (ERAS), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@howardsmithlaw.com, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.
What Happened?
On April 27, 2026, before market hours, Erasca disclosed that it had received a letter from legal counsel for Revolution Medicines, Inc. (“RevMed”) alleging that Erasca’s drug candidate, ERAS-0015, infringes a RevMed patent and is connected to alleged trade secret misappropriation. RevMed also claimed that Erasca had “improperly compared preclinical data of ERAS-0015 and RMC-6236 in public disclosures” and demanded Erasca cease making “deceptive and untrue comparative statements comparing ERAS-0015 and RMC-6236.”
On this news, Erasca’s stock price fell $2.34, or 10.9%, to close at $19.15 per share on April 27, 2026, thereby injuring investors.
That same day, after market hours, Erasca reported preliminary Phase 1 clinical data from ERAS-0015, revealing that a patient had died approximately one month after starting ERAS-0015.
On this news, Erasca’s stock price fell $9.25, or 48.3%, to close at $9.90 per share on April 28, 2026, thereby injuring investors further.
Contact Us To Participate or Learn More:
If you purchased Erasca securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Law Offices of Howard G. Smith
3070 Bristol Pike, Suite 112
Bensalem, Pennsylvania 19020
Telephone: (215) 638-4847
Email: howardsmith@howardsmithlaw.com
Visit our website at: www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260612961342/en/
Media gallery
